AstraZeneca raised its 2014 sales forecast for the second quarter in a row on Thursday, as the delayed arrival of Nexium generics in the United States kept cash flowing from the heartburn and ulcer pill. Britain's second biggest drugmaker, which saw off a $118 billion takeover approach from Pfizer in May, now expects revenue this year to grow in low single digits at constant exchange rates, after previously being seen flat.Sales in the third quarter rose 5 percent to $6.54 billion, generating "core" earnings, which exclude certain items, down 13 percent at $1.05 a share.Industry analysts, on average, had forecast sales in the quarter of $6.41 billion and earnings of $1.03 a share, according to Thomson Reuters.For the full year, core EPS is now expected to decrease at around 10 percent at constant rates -- better than anticipated previously -- although currency is expected to impact negatively by around 5 percent, assuming current exchange rates.
Thomson Reuters Corporation (Thomson Reuters) is a provider of information for the world?s businesses and professionals. Shares of TRI traded higher by 1.66% or $0.62/share to $37.86. In the past year, the shares have traded as low as $33.21 and as high as $38.73. On average, 744271 shares of TRI exchange hands on a given day and today's volume is recorded at 711898.
Thomson Reuters Corporation (Thomson Reuters) is a provider of information for the world?s businesses and professionals. Shares of TRI traded higher by 1.53% or $0.65/share to $43.13. In the past year, the shares have traded as low as $36.86 and as high as $43.26. On average, 686972 shares of TRI.TO exchange hands on a given day and today's volume is recorded at 563768.
Source
